SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq:MEND) today announced it has enrolled the first patient in the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT), an investigational device exemption (IDE) study designed to compare clinical outcomes between patients treated with the Company’s Pharos™ Vitesse™ Balloon Expandable Stent and the current best medical practice. The patient was treated by Dr. Monika Killer-Oberpfalzer, the Principal Investigator for the VISSIT Study at the Neuroscience Institut Salzburg of the Paracelsus Medical University in Salzburg, Austria.
